Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration

BMJ case reports

Volumn 2018, Issue , 2018, Pages

  Klein, Klara ^a   Asaad, Shonda ^b   Econs, Michael ^c   Rubin, Janet E ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b Southeastern Medical Oncology   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

calcium and bone; contraindications and precautions; gastrointestinal system; haematology (drugs and medicines)

Indexed keywords

FERRIC CARBOXYMALTOSE; FERRIC ION; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 23; MALTOSE; PHOSPHATE;

ANALOGS AND DERIVATIVES; CASE REPORT; CHEMICALLY INDUCED; COMPLICATION; CROHN DISEASE; DIFFERENTIAL DIAGNOSIS; DRUG EFFECT; HUMAN; HYPOPHOSPHATEMIA; INTRAVENOUS DRUG ADMINISTRATION; IRON DEFICIENCY ANEMIA; MALE; MIDDLE AGED; OSTEOMALACIA; PROCEDURES; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVENOUS; ANEMIA, IRON-DEFICIENCY; CROHN DISEASE; DIAGNOSIS, DIFFERENTIAL; FERRIC COMPOUNDS; FIBROBLAST GROWTH FACTORS; HUMANS; HYPOPHOSPHATEMIA; MALE; MALTOSE; MIDDLE AGED; OSTEOMALACIA; PHOSPHATES; TREATMENT OUTCOME;

EID: 85052243748     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr-2017-222851     Document Type: Article

References (0)